Highest-materiality recent filing
Silo Pharma raises $4M in private placement; warrants could add $7.7M
Issued 619,965 shares (or pre-funded warrants) at $6.452/share plus Series A-3 and A-4 warrants.
Silo Pharma announces 1-for-15 reverse stock split effective June 2, 2026
Every 15 shares of common stock combined into 1 share; par value unchanged at $0.0001.
Silo Pharma authorizes $1M buyback; pays IR consultant 848k shares
Board approved stock repurchase program up to $1 million of common stock.
Silo Pharma receives Nasdaq extension until June 22, 2026 to regain minimum bid price compliance
Company failed to meet $1.00 minimum bid price requirement by initial Dec. 24, 2025 deadline.
Silo Pharma shareholders approve 1:2-1:20 reverse split and increase equity plan shares to 1.4M
Reverse split authorized at ratio from 1-for-2 to 1-for-20, board may implement before October 24, 2026.
Silo Pharma launches crypto treasury strategy; appoints Corwin Yu to advisory board
Board established Crypto Advisory Board (up to 3 members); appointed Corwin Yu as first member.
Silo Pharma receives Nasdaq deficiency notice for bid price below $1.00
Nasdaq notified Silo of non-compliance with minimum bid price rule after 30 consecutive business days below $1.00, from May 14 to June 26, 2025.
Silo Pharma closes $2M public offering of common stock and warrants
Offered 3,333,338 shares (or pre-funded warrants) plus Series A-1 and A-2 warrants for up to 3,333,338 shares each.
Silo Pharma issues shareholder letter: SPC-15 IND expected 2025, SP-26 animal studies in early 2025
IND submission for SPC-15 intranasal PTSD treatment expected in 2025; Phase 1 trial to follow upon FDA approval.
Silo Pharma enters exclusive global license with Columbia University for PTSD candidate SPC-15
License covers patents and technical info for SPC-15, an intranasal treatment for stress-induced affective disorders and PTSD.
Silo Pharma submits pre-IND to FDA for SPC-15 intranasal PTSD treatment
SPC-15 is an intranasal prophylactic treatment for PTSD and stress-induced anxiety disorder.
Silo Pharma files provisional patent for ketamine pain management (SP-26) targeting fibromyalgia.
Provisional patent titled 'Methods and Compositions for Pain Management' covers chronic pain including fibromyalgia.
Silo Pharma receives U.S. patent covering SPC-15 for stress-induced affective disorders
USPTO issued U.S. Patent 11,491,120 for SPC-15, a prophylactic using ketamine for anxiety and PTSD in females.
Silo Pharma hires Eric Weisblum as CEO with $350K salary, extends Columbia research pact
Eric Weisblum appointed CEO; base salary $350K/yr, signing bonus $100K, annual bonus up to $350K.
Closed underwritten offering of 1,150,000 shares (incl. full over-allotment) at $5.00/share, gross proceeds $5.75M, net ~$4.83M.
Silo Pharma implements 1-for-50 reverse stock split in preparation for Nasdaq uplisting
Reverse split at ratio of 1-for-50 effective 4:01 p.m. ET on September 14, 2022.
Silo Pharma shareholders approve reverse stock split of 1-for-5 to 1-for-50
Shareholders granted Board discretion to effect a reverse split at a ratio between 1:5 and 1:50.
On October 12, 2022, the Company entered into an employment agreement with Eric Weisblum (the “Weisblum Employment Agreement”)
On September 27, 2022, the Board appointed Daniel Ryweck as Chief Financial Officer of the Company
On September 27, 2022, Eric Weisblum resigned as our Chief Financial Officer.
On September 27, 2022, the Company’s Board of Directors (the “Board”) appointed Jeff Pavell as a member of the Board.
Max materiality 0.90 · Median 0.50 · Most common event other_material